Antithrombotic Drug Therapy in Cardiovascular Disease
Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications...
| Corporate Author: | |
|---|---|
| Other Authors: | , |
| Format: | Electronic |
| Language: | English |
| Published: |
Totowa, NJ :
Humana Press : Imprint: Humana Press,
2010.
|
| Series: | Contemporary Cardiology
|
| Subjects: | |
| Online Access: | https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1007/978-1-60327-235-3 |
Table of Contents:
- The Platelet in Arterial and Venous Thrombosis
- The Coagulation Cascade in Arterial and Venous Thrombosis
- The Link Between Thrombosis and Inflammation
- Genetics of Thrombosis
- Aspirin for Primary and Secondary Prevention
- Thienopyridines in Stable CAD Patients
- Anti-platelet Therapies: Aspirin, Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors
- Unfractionated Heparin and Enoxaparin
- The Direct Thrombin Ihibitors
- Synthetic Factor Xa Inhibition, Fondaparinux
- Antiplatelet Therapies: Aspirin,Clopidogrel and thienopyridines and Glycoprotien IIb/IIIa Inhibitors
- Antithrombin Therapies: Unfractionated Heparin, Enoxaparin, Direct Thrombin Inhibitors, Fondaparinux
- Fibrinolysis and Facilitated PCI
- Antithrombotic Therapy in Percutaneous Coronary Intervention
- Antithrombotic Therapy in Carotid and Peripheral Intervention
- Monitoring of Antithrombotic Therapies
- Antithrombotic Therapy for DVT/PE
- Fibrinolysis for PE
- Duration of Anticoagulation Following VTE.-Antithrombotic Therapy for Atrial Fibrillation
- Antithrombotic Therapy for Valvular Heart Disease
- Antithrombotic Therapy for Cardiomyopathy
- Heparin-Induced Thrombocytopenia
- "Resistance" to Antiplatelet Therapies.